GB1350197A - Treatment of heart diseases - Google Patents
Treatment of heart diseasesInfo
- Publication number
- GB1350197A GB1350197A GB192273A GB192273A GB1350197A GB 1350197 A GB1350197 A GB 1350197A GB 192273 A GB192273 A GB 192273A GB 192273 A GB192273 A GB 192273A GB 1350197 A GB1350197 A GB 1350197A
- Authority
- GB
- United Kingdom
- Prior art keywords
- phosvitin
- crude
- heart
- magnesium sulphate
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000019622 heart disease Diseases 0.000 title abstract 2
- 102100027992 Casein kinase II subunit beta Human genes 0.000 abstract 5
- 101710158100 Casein kinase II subunit beta Proteins 0.000 abstract 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 abstract 2
- 235000019341 magnesium sulphate Nutrition 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 102000002322 Egg Proteins Human genes 0.000 abstract 1
- 108010000912 Egg Proteins Proteins 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 102000007982 Phosphoproteins Human genes 0.000 abstract 1
- 108010089430 Phosphoproteins Proteins 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 235000013345 egg yolk Nutrition 0.000 abstract 1
- 210000002969 egg yolk Anatomy 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 abstract 1
- 229940033663 thimerosal Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT48280/72A IT1061603B (it) | 1972-02-11 | 1972-02-11 | Medicamento e preparati farmaceutici che lo contengono come principio attivo |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1350197A true GB1350197A (en) | 1974-04-18 |
Family
ID=11265653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB192273A Expired GB1350197A (en) | 1972-02-11 | 1973-01-15 | Treatment of heart diseases |
Country Status (7)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8507651B2 (en) | 2002-11-27 | 2013-08-13 | Dmi Acquisition Corp. | Treatment of diseases and conditions mediated by increased phosphorylation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1743003A (en) * | 1926-03-31 | 1930-01-07 | Soc Of Chemical Ind | Phosphorus compound from animal proteids and process of manufacture thereof |
-
0
- BE BE795269D patent/BE795269A/xx not_active IP Right Cessation
-
1972
- 1972-02-11 IT IT48280/72A patent/IT1061603B/it active
-
1973
- 1973-01-10 IL IL41274A patent/IL41274A/xx unknown
- 1973-01-15 CA CA161,262A patent/CA989731A/en not_active Expired
- 1973-01-15 GB GB192273A patent/GB1350197A/en not_active Expired
- 1973-01-23 DE DE2303047A patent/DE2303047A1/de active Pending
- 1973-02-09 FR FR7304636A patent/FR2171353B1/fr not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8507651B2 (en) | 2002-11-27 | 2013-08-13 | Dmi Acquisition Corp. | Treatment of diseases and conditions mediated by increased phosphorylation |
Also Published As
Publication number | Publication date |
---|---|
IL41274A (en) | 1975-12-31 |
DE2303047A1 (de) | 1973-08-23 |
FR2171353B1 (US08197722-20120612-C00042.png) | 1976-08-13 |
IL41274A0 (en) | 1973-03-30 |
CA989731A (en) | 1976-05-25 |
IT1061603B (it) | 1983-04-30 |
FR2171353A1 (US08197722-20120612-C00042.png) | 1973-09-21 |
BE795269A (fr) | 1973-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Abel et al. | On the presence of histamine (B-Iminazolylethylamine) in the hypophysis cerebri and other tissues of the body and its occurrence among the hydrolytic decomposition products of proteins | |
Harington et al. | The isolation of l-thyroxine from the thyroid gland by the action of proteolytic enzymes | |
US3895107A (en) | CSA and CSC in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals | |
Glass | Gastric Mucin and its Constituents: Physico-Chemical Characteristics, Cellular Origin, Physiological Significance | |
US4234570A (en) | Proteinic active substances | |
US3895106A (en) | Novel CSA and CSC for use in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals | |
GB1455487A (en) | Pharmaceutical compositions | |
US3461205A (en) | Process of extracting proteins from potatoes | |
GB2171302A (en) | Therapeutic hydroxyprolines | |
GB1350197A (en) | Treatment of heart diseases | |
US3697563A (en) | (3,4,5-trimethoxy-benzamido)-alkanoic acids for prophylaxis and treatment of cardiac disorders | |
Weiner et al. | Significance of loss of serum protein in therapy of severe burns | |
Hawking et al. | Miracil D, its toxicology, absorption, and excretion in animals and human volunteers | |
SU871721A3 (ru) | Способ получени биологически активного вещества,обладающего способностью усиливать секрецию инсулина и улучшать глюкозную толерантность | |
Braun-Menéndez et al. | Pressor polypeptides formed in vivo and in vitro as mediators of renal hypertension | |
US3966915A (en) | Treatment of heart diseases | |
US2770570A (en) | Method of obtaining intrinsic factor preparations of enhanced potency | |
US4169139A (en) | Glyco/proteinaceous materials derivable from beef liver and other tissues useful for the treatment of toxic and allergic conditions | |
WO1982003388A1 (en) | Peptides with nerve-regenerating properties | |
Formijne | Experiments on the properties of the extrinsic factor and on the reaction of Castle | |
US3140230A (en) | Method of stimulating the cardiac and bronchial branches of the central nervous system | |
US3002888A (en) | Lipid-mobilizing composition | |
GB1247886A (en) | Therapeutic immunoglobulins and process for their production | |
US3153616A (en) | Method of producing a substance having new strong physiological actions from human or cattle saliva | |
US3268409A (en) | Treatment of hepatic degeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed [section 19, patents act 1949] | ||
PCNP | Patent ceased through non-payment of renewal fee |